Poland: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Poland

The Polish prophylactic medicaments containing insulin market declined to $X in 2022, remaining relatively unchanged against the previous year. The market value increased at an average annual rate of +1.9% over the period from 2012 to 2022; however, the trend pattern remained relatively stable, with somewhat noticeable fluctuations being observed throughout the analyzed period. As a result, consumption reached the peak level of $X. From 2015 to 2022, the growth of the market remained at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Poland

In value terms, prophylactic medicaments containing insulin production reduced slightly to $X in 2022 estimated in export price. Over the period under review, production continues to indicate a relatively flat trend pattern. The pace of growth appeared the most rapid in 2014 with an increase of 21% against the previous year. As a result, production attained the peak level of $X. From 2015 to 2022, production growth failed to regain momentum.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from Poland

In 2022, shipments abroad of medicaments containing insulin but not antibiotics in measured doses was finally on the rise to reach X tons for the first time since 2019, thus ending a two-year declining trend. Overall, total exports indicated a remarkable increase from 2012 to 2022: its volume increased at an average annual rate of +6.9% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth appeared the most rapid in 2017 with an increase of 57%. The exports peaked in 2022 and are likely to see gradual growth in the near future.

In value terms, prophylactic medicaments containing insulin exports skyrocketed to $X in 2022. Over the period under review, exports, however, saw a noticeable downturn. Over the period under review, the exports attained the maximum at $X in 2014; however, from 2015 to 2022, the exports remained at a lower figure.

Exports by Country

China (X tons), Vietnam (X tons) and Sudan (X tons) were the main destinations of prophylactic medicaments containing insulin exports from Poland, with a combined 79% share of total exports. The Philippines, Ukraine, Libya and Paraguay lagged somewhat behind, together accounting for a further 14%.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by Paraguay (with a CAGR of +380.3%), while the other leaders experienced more modest paces of growth.

In value terms, China ($X) emerged as the key foreign market for medicaments containing insulin but not antibiotics in measured doses exports from Poland, comprising 49% of total exports. The second position in the ranking was taken by Vietnam ($X), with a 22% share of total exports. It was followed by Sudan, with an 8.3% share.

From 2012 to 2022, the average annual rate of growth in terms of value to China stood at +17.0%. Exports to the other major destinations recorded the following average annual rates of exports growth: Vietnam (+16.8% per year) and Sudan (0.0% per year).

Export Prices by Country

The average prophylactic medicaments containing insulin export price stood at $X per ton in 2022, surging by 25% against the previous year. In general, the export price, however, showed a abrupt downturn. The export price peaked at $X per ton in 2014; however, from 2015 to 2022, the export prices stood at a somewhat lower figure.

There were significant differences in the average prices for the major external markets. In 2022, amid the top suppliers, the country with the highest price was China ($X per ton), while the average price for exports to Vietnam ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to Libya (+23.4%), while the prices for the other major destinations experienced a decline.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into Poland

In 2022, prophylactic medicaments containing insulin imports into Poland declined rapidly to X tons, falling by -21.1% against the previous year. Over the period under review, imports recorded a relatively flat trend pattern. The growth pace was the most rapid in 2021 with an increase of 21%. Imports peaked at X tons in 2015; however, from 2016 to 2022, imports stood at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin imports reduced to $X in 2022. Overall, imports showed a perceptible downturn. The pace of growth appeared the most rapid in 2017 when imports increased by 12%. Imports peaked at $X in 2014; however, from 2015 to 2022, imports remained at a lower figure.

Imports by Country

Brazil (X tons), Italy (X tons) and France (X tons) were the main suppliers of prophylactic medicaments containing insulin imports to Poland, with a combined 82% share of total imports. Denmark, China, Germany and the United States lagged somewhat behind, together comprising a further 17%.

From 2012 to 2022, the biggest increases were recorded for the United States (with a CAGR of +50.4%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, Brazil ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Poland, comprising 45% of total imports. The second position in the ranking was held by Italy ($X), with a 21% share of total imports. It was followed by Denmark, with a 14% share.

From 2012 to 2022, the average annual growth rate of value from Brazil stood at -5.9%. The remaining supplying countries recorded the following average annual rates of imports growth: Italy (+3.2% per year) and Denmark (+2.0% per year).

Import Prices by Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $X per ton, growing by 19% against the previous year. Overall, the import price, however, recorded a perceptible curtailment. Over the period under review, average import prices reached the peak figure at $X per ton in 2012; however, from 2013 to 2022, import prices failed to regain momentum.

There were significant differences in the average prices amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for China ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by China (+68.8%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :